Overview

A Trial of CXD101 in Combination With Nivolumab in Patients With Metastatic Microsatellite-Stable Colorectal Cancer

Status:
Unknown status

Trial end date:
2020-06-15

Target enrollment:

Participant gender:

Summary

This is a study to assess the safety and efficacy of CXD101 in combination with the PD-1 Inhibitor Nivolumab in patients with metastatic, previously-treated, Microsatellite-Stable (MSS) Colorectal Carcinoma (CRC). The primary hypothesis of this study is that CXD101 and anti-PD1 monoclonal antibody synergise the anti-tumour activity in MSS colorectal cancer patients (~95% of CRC) who do not seem to respond to anti-PD1 or -PD-L1 immunotherapy alone.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Celleron Therapeutics Ltd.

Treatments:

Nivolumab